Effects of monosialoganglioside GM1 in experimental models of ischemic brain damage.
Systemic administration of monosialoganglioside GM1 is efficacious in reducing excitatory amino acid (EAA)-related neurotoxicity in vivo following intracerebroventricular injection of N-methyl-D-aspartate (NMDA) in 7-day-old rats. Five days later, NMDA-treated animals showed extensive brain damage which was accompanied by significant decreases in brain weight, choline acetyltransferase activity and 3H-ouabain binding. All these neurotoxic effects were significantly reduced with ganglioside treatment. Since excessive activation of EAAS is implicated in hypoxic-ischemic brain damage, these results favor the hypothesis that a similar effect is involved in the ability of ganglioside to ameliorate outcome following cerebral ischemia.
Lipartiti
M
M
Laboratori di Ricerca Fidia, Abano Terme, Padova.
Lazzaro
A
A
Zanoni
R
R
Bonvento
G
G
Mazzari
S
S
D000818:Animals; D001921:Brain / Q000201:enzymology / Q000473:pathology; D001925:Brain Damage, Chronic / Q000188:drug therapy / Q000473:pathology; D002545:Brain Ischemia / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D005677:G(M1) Ganglioside / Q000008:administration & dosage / Q000627:therapeutic use*; D007276:Injections, Intraventricular; D016202:N-Methylaspartate; D009929:Organ Size / Q000187:drug effects; D010042:Ouabain / Q000378:metabolism; D051381:Rats
D005677:G(M1) Ganglioside; D010042:Ouabain; D016202:N-Methylaspartate; D002795:Choline O-Acetyltransferase